## **SANOFI S.A.**

ISIN: FR0000120578 WKN: 12057 Asset Class: Stock



## **Company Profile**

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

|                                | 20             | <b>2023</b> Assets Liabilities and equity |                | <b>2022</b> Assets Liabilities and equity |                | <b>2021</b> Assets Liabilities and equity |  |
|--------------------------------|----------------|---|----------------|---|----------------|---|--|
| Financial figures              |                |   |                |   |                |   |  |
| Current assets                 | 30,655,000,000 |   | 34,026,000,000 |   | 30,564,000,000 |   |  |
| Common stock capital           |                | 2,530,000,000                             |                | 2,522,000,000                             |                | 2,527,000,000                             |  |
| Fixed assets                   | 95,809,000,000 |   | 92,696,000,000 |   | 89,678,000,000 |   |  |
| Equity capital of a company    |                | 74,353,000,000                            |                | 75,152,000,000                            |                | 69,031,000,000                            |  |
| Cash and cash equivalents      | 8,710,000,000  |   | 12,736,000,000 |   | 10,098,000,000 |   |  |
| Accrued liabilities            |                | 5,262,000,000                             |                | 5,822,000,000                             |                | 6,430,000,000                             |  |
| Other assets                   | -              |   | -              |   | -              |   |  |
| Current liabilities            |                | 24,194,000,000                            |                | 23,964,000,000                            |                | 21,295,000,000                            |  |
| Prepayments and accrued income | -              |   | -              |   | -              |   |  |
| Non-current liabilities        |                | 27,917,000,000                            |                | 27,606,000,000                            |                | 29,916,000,000                            |  |
| Different income               |                | -   |                | -   |                | -   |  |
| Other liabilities              |                | 4,696,000,000                             |                | 3,182,000,000                             |                | 2,907,000,000                             |  |
|                                |                |   |                |   |                |   |  |

| Total assets        | 126,464,000,000 | 126,464,000,000 | 126,722,000,000 | 126,722,000,000 | 120,242,000,000 | 120,242,000,00 |
|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|
|                     |                 |                 |                 |                 |                 |                |
| Balance notes       |                 |                 |                 |                 |                 |                |
|                     |                 |                 |                 | 2023            | 2022            | 202            |
| Accounting standard |                 |                 |                 | IFRS            | IFRS            | IFR            |
| Employees           |                 |                 |                 | 87,994          | 91,573          | 95,44          |
| Equity ratio        |                 |                 |                 | 59.04%          | 59.60%          | 57.709         |
| Debt-equity ratio   |                 |                 |                 | 69.37%          | 67.80%          | 73.319         |
| Others              |                 |                 |                 |                 |                 |                |
|                     |                 |                 |                 | 2023            | 2022            | 202            |
| Tax Expense Rate    |                 |                 |                 | 22.40%          | 19.25%          | 19.98%         |

## **SANOFI S.A.**

ISIN: FR0000120578 WKN: 12057 Asset Class: Stock

| Income statement   |                |                |                |
|--|----------------|----------------|----------------|
|  | 2023           | 2022           | 2021           |
| Turnover   | 43,070,000,000 | 42,997,000,000 | 37,761,000,000 |
| Net income   | 5,400,000,000  | 8,371,000,000  | 6,223,000,000  |
| EBIT   | 7,701,000,000  | 10,660,000,000 | 8,171,000,000  |
| Operating income before taxes                                | 7,153,000,000  | 10,422,000,000 | 7,798,000,000  |
| Cash Flow  | 10,258,000,000 | 10,526,000,000 | 10,522,000,000 |
| Net interest income  | -548,000,000   | -238,000,000   | -373,000,000   |
| Research and development expenses                            | 6,725,000,000  | 6,705,000,000  | 5,689,000,000  |
| Income taxes   | 1,602,000,000  | 2,006,000,000  | 1,558,000,000  |
| Result from investments in subsidaries, associates and other | -115,000,000   | 68,000,000     | 39,000,000     |
| Revenues per employee  | 489,465        | 469,538        | 395,643        |

| <b>Board of Directors</b> |                               |
|---------------------------|-------------------------------|
|                           |                               |
| Frédéric Oudéa            | Chairman of Supervisory Board |
| Antoine Yver              | Member of Supervisory Board   |
| Emile Voest               | Member of Supervisory Board   |
| John Sundy                | Member of Supervisory Board   |
| Wolfgang Laux             | Member of Supervisory Board   |
| Anne-Francoise Nesmes     | Member of Supervisory Board   |
| Barbara Lavernos          | Member of Supervisory Board   |
| Carole Ferrand            | Member of Supervisory Board   |
| Christophe Babule         | Member of Supervisory Board   |
| Clotilde Delbos           | Member of Supervisory Board   |
| Fabienne Lecorvaisier     | Member of Supervisory Board   |
| Gilles Schnepp            | Member of Supervisory Board   |
| Lise Kingo                | Member of Supervisory Board   |
| Patrick Kron              | Member of Supervisory Board   |
| Rachel Duan               | Member of Supervisory Board   |
| Yann Tran                 | Member of Supervisory Board   |
|                           |                               |

| Members of Management Board |                               |  |
|-----------------------------|-------------------------------|--|
| Paul Hudson                 | Chairman of Managing Board    |  |
| Brendan O'Callaghan         | Member of Executive Committee |  |
| Brian Foard                 | Member of Executive Committee |  |
| Emmanuel Frenehard          | Member of Executive Committee |  |
| Francois Roger              | Member of Executive Committee |  |
| Houman Ashrafian            | Member of Executive Committee |  |
| Julie Van Ongevalle         | Member of Executive Committee |  |
| Madeleine Roach             | Member of Executive Committee |  |
| Natalie Bickford            | Member of Executive Committee |  |
| Olivier Charmeil            | Member of Executive Committee |  |
| Roy Papatheodorou           | Member of Executive Committee |  |
| Thomas Triomphe             | Member of Executive Committee |  |